# 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)

> **NCT04553926** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 661 (actual)

## Conditions studied

- Ovarian Cancer
- Breast Cancer
- Prostate Cancer
- Pancreatic Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04553926
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-01
- **Primary completion:** 2025-07-11
- **Final completion:** 2025-07-11
- **Target enrollment:** 661 (ACTUAL)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04553926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04553926, "'OLAP' (OLAparib Regulatory Post-marketing Surveillance)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04553926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*